Completed Venture Grant Archive

2016 Consensus conference for the revision of the diagnostic criteria of PSP Dr. Guenter Hoeglinger Klinikum rechts der Isar der TU Muenchen, Munich, Germany
2014 Elucidating PSP Genotype-Phenotype Relationships Using Human Isogenic iPSCs Dr. John Steele University of California, San Diego, CA
2014 Synaptic Tau-Proteasome Dysfunction and a Potential Therapeutic Strategy Dr. Natura Myeku Columbia University, New York, NY
2013 Epigenetic Modifications in PSP Dr. Ulrich Mueller University of Giessen, Germany
2014 Spreading of a Synuclein Pathology in Multiple System Atrophy Dr. Johannes Brettschneider University of Ulm, Germany
2014 Selective Cell Vulnerability in MSA Dr. Eduardo Benaroch Mayo Clinic , Jacksonville, FL
2013 Urso Student Fellowship Mr. John Titus Duke University Medical Center, Durham, NC
2013 The Role of O-Linked Protein Glycosylation in the Spread of Tau Pathology Dr. Christoph Wiessner Asceneuron SA, Switzerland
2013 Altering Tau Splicing for PSP and Other 4R Tauopathies Dr. Michael Wolfe Harvard Medical School, Boston, MA
2013 Follow-Up Genotyping & Functional Analysis of PSP H1 Haplotype Variants Dr. Pau Pastor Foundation for Applied Medical Research, Pamplona, Spain
2013 Eloise H. Troxel Brain Bank Dr. Dennis Dickson Mayo Clinic , Jacksonville, FL
2013 Urso Student Fellowship Mrs. Emily Beiser Rutger University, New Brunswick, NJ
2013 Mechanisms and Therapy for Tauopathy based on RNA Binding Proteins Dr. Benjamin Wolozin Boston University, Boston, MA
2013 Tau Dimerization: A Mechanism of Tau Function and Dysfunction? Dr. Stuart Feinstein  University of California, Santa Barbara, CA
2012 PSP Whole Exome Study Phase Two Dr. Gerad Schellenberg  University of Pennsylvania, Philadelphia, PA
2012 Splice Variant Markers for PSP Dr. Judith Potashkin Rosalind Franklin University of Medicine and Science
2012 Eloise H. Troxel Brain Bank Dr. Dennis Dickson Mayo Clinic , Jacksonville, FL
2012 Tracking Progressive Neurodegeneration in PSP Using Diffusion Tensor MRI  Dr. Massimo Filippi Vita-Salute San Raffaele University, Milan, Italy
2012 Identifying Functional Genetic Risk Factors for PSP by RNA-seq Dr. Nilufer Ertekin-Taner  Mayo Clinic, Jacksonville, FL
2012 Gene Expression and Neuropathology Endophenotypes for Gene Discovery in PSP Dr. Nilufer Ertekin-Taner  Mayo Clinic, Jacksonville, FL
2012 Mechanisms of Tau and ER Stress for Novel PSP and CBD Therapeutics Dr. Jose Abisambra  University of South Florida, Tampa, FL
2012 An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to the AL-108-231 of Davunetide for the Treatment of Non-PSP Predicted Tauopathies: CBD, Progressive Nonfluent Aphasia and FTD with Parkinsonism Linked to Chromosome 17 Dr. Adam Boxer  University of California, San Francisco, CA
2012 PSP Whole Exome Study  Dr. Gerard Schellenberg  University of Pennsylvania, Philadelphia, PA
2011 Eloise H. Troxel Brain Bank Dr. Dennis Dickson Mayo Clinic, Jacksonville, FL
2011 Models to Determine the Toxicity of Tau Aggregates Dr. Chris  Gamblin University of Kansas, Lawrence, KS
2011 Evaluating Reduced Tau Levels as a Therapy for PSP and CBD Dr. Timothy Miller Washington University School of Medicine, St. Louis, MO
2011 Epigenetic Modifications in PSP Dr. Ulrich Mueller University Hospital Giessen & Marburg, Giessen, Germany
2011 CHIP-Mediated Regulation of Hsp90 High Affinity Complex Dr. Leonard Petrucelli Mayo Clinic, College of Medicine, Jacksonville, FL         
2011 Manipulating the Substrate Specificity Program in the Chaperone System to remove Tau in PSP and CBD Dr. Chad Dickey  University of South Florida, Tampa, FL
2010 A Pilot Clinical Trial of NAP (AL-108) for CBD and Frontotemporal Lobar Degeneration with Predicted CBD Pathology Dr. Adam Boxer Regents of the University of California, San Francisco, CA
2010 Pathogenetic Mechanisms of Progressive Supranuclear Palsy and Corticobasal Degeneration Dr. Gerard Schellenberg University of Pennsylvania, Philadelphia, PA
2010 PSP/CBD Genome-Wide Association Analysis follow-up and replication Dr. Gerard Schellenberg University of Pennsylvania, Philadelphia, PA
2010 Eloise H. Troxel Brain Bank Dr. Dennis Dickson Mayo Clinic, Jacksonville, FL
2010 Tau and its Pathology in Neurons derived from Induced Pluripotent Stem Cells of FTDP-17T Patients with PSP-Like Tau Pathology Dr. Maria Spillantini  University of Cambridge, Cambridge, UK
2010 Autophagic Modulation and Clearance of Tau Aggregates Dr. Ho Yu Columbia University Medical Center, New York, NY
2009 Modeling Haplotype-Specific Gene Function at the MAPT Locus in 4R Tauopathy Dr. Richard Wade-Martins University of Oxford, Oxford, UK
2009 Inhibition of Tau Pathology in Transgenic Mouse Models with an Optimized Orally Active Tau Kinase Inhibitor Dr. Hanno Roder TauTaTis, Inc, Jacksonville, FL
2009 MicroRNA Regulation of MAPT in CBD and Related Tauopathies  Dr. Rosa Rademakers Mayo Clinic Jacksonville, FL
2009 Structural Polymorphism of Tau Filaments in CBD Dr. Martin Margittai University of Denver, Denver, CO
2009 Comparative Proteomics of CBD & PSP Brain to Identify Biomakers Dr. Shu-Hui  Yen Mayo Clinic, Jacksonville, FL
2009 Development of Activators of Puromycin Sensitive Aminopeptidase to Treat CBD Dr. Stanislav Karsten Los Angeles Biomedical Research Institute, Torrance, CA
2009 Tau-Mediated Effects Upon Microtubule Structure and Kinesin Translocation Dr. Stuart Feinstein Regents of the University of California, Santa Barbara, CA
2009 In Vivo Identification of Pharmacological Treatments for Tauopathy Dr. Mel Feany Brigham and Women’s Hospital, Boston, MA
2009 HSP-Peptide Complex Mediated Immunization in a Mouse Model of Tauopathy Dr. Michael DeTure Mayo Clinic Jacksonville, FL
2009 Genomewide Identification of Transregulators of Tau Gene Expression & Splicing Dr. Rohan deSilva Institute of Neurology, UCL,  Queen Square, London
2009 A Pilot Clinical Trial of NAP (AL-108) for CBD and Frontotemporal Lobor Degeneration with Predicted CBD Pathology Dr. Adam Boxer Regents of the University of California, San Francisco, CA
2009 Polyphenols from Grape Seeds as a Potential Therapeutic Agent in Taupathies Dr. Giulio Pasinetti Mount Sinai School of Medicine, New York, NY
2009 The Effects of CBD-Associated Tau Gene H1 Haplotype on Tau Expression Dr. Hana Dawson Duke University Medical Center, Durham, NC
2009 Targeting Hsp70 as a Therapeutic Strategy for CBD and Other Taupathies Dr. Chad Dickey University of South Florida, Tampa, FL
2009 The Role of Microglial-Meditated Neuroinflamation in Fronto-Temporal Dementia Tau Pathology Dr. Kiran Bhaskar Cleveland Clinic, Clevelnd, OH
2009 Eloise H. Troxel Brain Bank Dr. Dennis Dickson Mayo Clinic, Jacksonville, FL
2008 Unilateral Pedunculopontine Deep Brain Stimulation in PSP Dr. Elena Moro University of Toronto, Toronto, ON
2008 Noninvasive Cortical Stimulation for Motor and Non-Motor Features of PSP and CBD Dr. Alan Wu University of California, Los Angeles, CA 
2008 Toward a Molecular Understanding of Tau Misfolding Dr. Martin Margittai University of Denver, Denver, CO
2008 Phenotypic Characterization of Tauopathy Zebrafish Dr. Edward Burton University of Pittsburgh, Pittsburg, PA
2008 Mapping Progressive Neurodegeneration in PSP using Transcranial Magnetic Stimulation and CSF-Tau Dr. David Williams Monash University, Australia
2007 Genome-Wide Association Study in PSP Dr. Dennis Dickson Mayo Clinic College of Medicine, Jacksonville, FL
2007 Genome-Wide Association Study in PSP Dr. Rohan deSilva Institute of Neurology, UCL,  Queen Square, London
2007 Genome-Wide Association Study in PSP Dr. Ulrich Müller University Hospital, Giessen, Germany
2007 Genome-Wide Association Study in PSP Dr. Hank Hakonarson Center for Applied Genomics, Philadelphia, PA
2007 Genome-Wide Association Study in PSP Dr. Bernie Devlin University of Pittsburgh, Pittsburg, PA
2007 Genome-Wide Association Study in PSP Dr. Gerard Schellenberg Geriatric Research Education and Clinical Center, Seattle, WA
2007 Longitudinal Prospective PSP Study Dr. Irene Litvan University of Louisville Health Sciences Center, Louisville, KY
2007 Haplotype regulation of alternative splicing at the MAPT locus Dr. Richard Wade-Martins University of Oxford, United Kingdom
2007 Unraveling Multi-Protein Chaperone Complexes in PSP and other Tauopathies Dr. Chad Dickey University of South Florida, Tampa, FL
2007 Genome-Wide Association Study in PSP Dr. Ulrich Muller University Hospital, Giessen, Germany
2007 Inhibition of Tau Pathology in Transgenic Mouse Models with an Optimized Orally Active Tau Kinase Inhibitor Dr. Hanno  Roder Mayo Clinic, Jacksonville, FL
2007 Strength Training Patients with PSP for Dysphagia Dr. Christine Sapienza University of Florida, Gainesville, FL
2007 Tau Aggregation in Oligodendrocytes and the Role of Thrombin Signaling Dr. Christine Richter-Landsberg University of Oldenburg, Germany
2006 Parkin and Tau Mutational Effects on Tangle Formation in PSP Dr. Parvoneh Navas University of Washington School of Medicine, Seattle, WA
2006 Finemapping of Risk Loci for PSP Identified in a Genome-Wide Scan Dr. Michael Hutton Mayo Clinic College of Medicine, Jacksonville, FL
2006 Interaction of Neuronal and Glial Tau in a Drosophila Model of Tauopathy Dr. Mel Feany Brigham and Women’s Hospital, Boston, MA
2006 Hypothesis- Driven Gene Profiling in an Animal Model of PSP Dr. Ronald Klein LSU Health Sciences Center, Shreveport, LA
2006 Studies of PSA Neuroprotective Role Using Transgenic Mouse Models Dr. Stanislav Karsten University of California, Los Angeles, CA
2005 AKT-Dependent Signaling in PSP and Transgenic Mouse Model of Tauopathy Dr. Hanna Ksiezak-Reding Mount Sinai School of Medicine, New York, NY
2005 Eloise H. Troxel Brain Bank Dr. Dennis Dickson Mayo Clinic, Jacksonville, FL
2005 Inhibiting Transglutaminase Splice Variants for Treatment of PSP Dr. Nancy Muma Loyola University Chicago, Maywood, IL
2005 Do PSP Associated TAU Polymorphisms Alter the Expression of the TAU Microtubule Binding Domain Dr. Hana Dawson Duke University Medical Center, Durham, NC
2005 Effect of Coenzyme Q10 in PSP: A Randomized, Multicenter, Placebo-Controlled, Double Blind Study Dr. Diana Apetauerova Lahey Clinic, Burlington, MA
2005 Proteomics Analysis of a Novel Murine Model of Astrocytic Tau Pathology in PSP Dr. Mark Forman University of Pennsylvania School of Medicine, Philadelphia, PA
2005 A Zebrafish Model of Tauopathy Dr. Edward  Burton University of Pittsburgh, Pittsburgh, PA
2004 PSP and a Failing Ubiquitin-Proteasome System Dr. FW van Leeuwen Netherlands Institute for Brain Research, The Netherlands
2004 Identification of Compounds that Modulate Exon 10 Splicing in the Tau Gene Dr. Jianhua Zhou University of Massachusetts Medical School, Worcester, MA
2004 Proteomis Analysis of Post Mortem PSP Brain Dr. Benoit Giasson University of Pennsylvania, Philadelphia, PA
2004 Heat Shock Proteins as Inhibitors of Tau Aggregation in Oligodendrocytes Dr. Christine Richter-Landsberg University of Oldenburg, Germany
2004 Proteomic Analysis of a Transgenic Mouse Model of Tauopathy Dr. Shu-Hui  Yen Mayo Clinic, Jacksonville, FL
2004 Assessment of Tau Protein Isoform profiles in Cerebrospinal Fluid of Tauopathy Patients as a Potential Diagnostic Biomarker Dr. Rohan de Silva, University College London, London, UK
2001 Eloise H. Troxel Brain Bank Dr. Dennis Dickson Mayo Clinic, Jacksonville, FL
2003 Parkin Mutations in a Mouse Model of PSP Dr. Parvoneh Navas University of Washington School of Medicine, Seattle, WA
2003 Correlation of Clinical Severity, Brain Inflammatory Changes & Apparent Water Diffusion Coefficients in PSP & Idiopathic Parkinson’s Disease Dr. David Brooks Imperial College School of Medicine London, UK
2003 Discovery of Tau Phosphorylation Inhibitors for the Treatment of PSP Dr. Kenneth Kosik Brigham and Women’s Hospital, Boston, MA
2003 Cystamine, a Transglutaminase Inhibitor, for the Treatment of Tauopathies, Especially in PSP Dr. Nancy Muma University of Washington,  Seattle, WA
2003 Formation Filamentous Tau Inclusions in Human Cells with Inducible Expression of Tau Proteins Dr. Shu-Hui  Yen Mayo Clinic, Jacksonville, FL
2003 Refining the Genetic and Functional Role of the Tau H1 Haplotype in Neurodegeneration Dr. Matt Farrer Mayo Clinic, Jacksonville, FL
2003 Aging Effects and Gene Therapy in a Novel Nigrostriatal Degeneration Model Dr. Ronald Klein LSU Health Sciences Center, Shreveport, LA
2003 Development and Characterization of a Novel Experimental Model of PSP Dr. Etienne Hirsch Salpetriere, Hospital de la, Paris, France
2003 Genetic Analysis of 17q21 Region Sporadic Tauopathies Dr. Alison Goate Washington University School of Medicine, St. Louis, MO
2003 Hyperphosphorylation, Tau Filaments and Neurodegeneration in a Transgenic Mouse Model of a Human Tauopathy Dr. Maria Spillantini University of Cambridge, Cambridge, UK
2003 Identification of Cis-Elements that Regulate Exon 10 Splicing in the Tau Gene Dr. Jianhua Zhou University of Massachusetts Medical School, Worcester, MA
2003 mRNA Profiling in the Postmortem PSP Brain: Target Identification Dr. Sarah Augood Massachusetts General Hospital, Boston, MA
2003 Diagnostic Protein Biomarker Discovery in PSP Dr. Lap Ho University of Washington School of Medicine, St. Louis, MO
2002 A Novel Approach for Neuroprotection in PSP Dr. Irene Litvan Henry M. Jackson Foundation, Bethesda, MD
2002 Efficacy of Environmental on a Mouse Models of Tauopathy Dr. Jada Lewis Mayo Clinic College of Medicine, Jacksonville, FL
2002 The Relationship of Guamanian Pigmentary Retinopathy to ALS/PDC of Guam Dr. John Steele Tamuning, Guam
2002 Prehistory of PSP: Bibliographic Search and Copying Dr. Adolfo Brusa Ospedalia Galliera, Italy
2002 Cross-Linking of Tau in PSP Neurofibrillary Dr. Nancy Muma Loyola University Chicago, Maywood, IL
2002 Characterization of Tau Auto-Antibodies in PSP Dr. James Tetrud The Parkinson’s Institute, Research and Treatment Center, CA
2002 Screening of Tau Mutation in a Unique PSP Family Dr. Rong Chen The Parkinson’s Institute, Basic Research, Sunnyvale, CA
2002 Analysis of the 17q21 Region in PSP, Tau Gene Analysis in Parkin’s Disease Dementia and in other Atypical Parkinsonims Dr. Eduardo Tolosa Neurology Service, Hospital Clinic, Barcelona, Spain
2002 Cortial and Striatal Cholinergic Receptor Subtypes in PSP, Alzheimer’s Disease and Dementia with Lewy Bodies Dr. David Burn Newcastle General Hospital, Regional Neuroscience Centre, UK
2002 Glial Tau Aggregates in PSP and Human Cultured Cells Dr. Hanna Ksiezak-Reding Mount Sinai School of Medicine, New York, NY
2002 Development of a Measure of Health-Related Quality of Life PSP Dr. Anette Schrag University College London, London, UK
2006 Eloise H. Troxel Brain Bank Dr. Dennis Dickson Mayo Clinic, Jacksonville, FL
2001 Finding the Cause and Effect of a Bioenergetic Defect in PSP Dr. David Albers Cornell University, Weill Medical College, New York, NY
2001 Interaction of Parkin Protein with Abnormal Tau Dr. Paul Fishman University of Maryland School of Medicine, Baltimore, MD
2001 Characterization of the Molecular Mechanisms Leading to PSP Dr. Justo Garcia de Yebenes Fundacion Jimenez Diaz, Madrid, Spain
2000 Regulation of Human Tau Gene Expression and it’s Role in PSP Dr. Jane Wu Washington University School of Medicine, St. Louis, MO
2001 Tau Auto-Antibody Production in PSP Dr. James Tetrud The Parkinson’s Institute, Research and Treatment Center, , CA
2001 Mechanisms Regulating Neurofibrillary Tangle Formation in PSP Dr. Nancy Muma University of Washington, Seattle, WA
2001 Comparison of Region Specific MRNA Expression Profiles of PSP Brains with those of Alzheimer, FTDP-17, Pick Disease & Non Affected Brains, using DNA Microarray Technology Dr. Vincenzo Bonifati Erasmus University Rotterdam, The Netherlands
2001 mRNA Profiling in the Postmortem PSP Brain: Identifying Abnormal Signaling Pathways Dr. Sarah Augood, Massachusetts General Hospital, Boston, MA
2001 Dopa-resistant Parkinsonism in Guadeloupe: Evaluation of Isoquinolines Derivates and Acetogenines Toxicity in Rats Dr. Dominique Caparros-Lefebvre University Hospital, Guadeloupe, France
2000 Effect of Lipoperxidation on cdk5 Activity and Tau Protein Aggregation: A Model of PSP Pathogenesis Dr. Massimo Tabaton University of Genova, Department of Neurosciences, Italy
2000 Are Matrix Metalloproteinases Involved in the Pathogenesis of PSP? Dr. David Albers Cornell University, Weill Medical College, New York, NY
2001 Regulation of Human Tau Gene Expression and it’s Role in PSP Dr. Jane Wu Washington University School of Medicine, St. Louis, MO
2000 Environmental Factors and Detoxification Mechanisms in PSP Dr. Rosemary Waring The University of Birmingham, Birmingham, UK
1999 Mutational Analysis of the Tau Gene in PSP Dr. Joseph Higgins New York State Dept. of Health, New York, NY
1999 Ultrastructural and Biochemical Hetergeneity of Paired Helical Filaments in PSP Dr. Hanna Ksiezak-Reding Mount Sinai School of Medicine, New York, NY
1999 Are Impairments of Energy Metabolism Contributory in PSP? Dr. Flint Beal, M. Flint, MD Cornell University, Weill Medical College, New York, NY
1999 Activity and Expression of Antioxidant Enzymes in the PSP Brain Dr. Sarah Augood Massachusetts General Hospital, Boston, MA
1999 Problems of Cell Death in PSP Dr. Kurt Jellinger University of Vienna School of Medicine, Austria
1999 Identification of the PSP Gene Dr. Parvoneh Navas University of Washington, Seattle, WA
1999 Role of the Thalmus in PSP and Parkinson’s Disease Dr. Jasmine Henderson Prince of Wales Medical Research Institute, Randwick, Australia
1999 Is Brain Oxidative Stress & Damage Characteristic of PSP? Dr. Stephen Kish Centre for Addiction & Mental Health, Toronto, ON, Canada
1999 Mechanisms of Neurofibrillary Tangle Formation in PSP Dr. Nancy Muma Loyola University Chicago, Maywood, IL
1999 Synaptic Protein Loss and Alterations in Growth Inhibitory Factors as a Biological Foundation of Behavioural Changes & Cognitive Decline in PSP Dr. Elizabeth Mukaetova-Ladinska University of Newcastle upon Tyne, UK
1998 Neuropathological Grading Scale for PSP Dr. Mark Becher University of New Mexico, Health Science Center, Albuquerque, NM
1998 Neuroanatomical Basis for PSP Eyelid Motor Dysfunction Dr. Mark LeDoux University of Tennessee, Memphis, TN
1998 Mitochondria in PSP Dr. Russell Swerdlow University of Virginia School of Medicine, Charlottesville, VA
1998 Tau Gene Mutations in PSP Dr. Joseph Higgins Laboratory of Clinical Neurogenetics, Wadsworth Center, Albany, NY
1998 Oxidative Mechanisms in PSP Dr. David Albers Massachusetts General Hospital, Neurology Dept., Boston, MA
1998 Molecular Studies of the Tau Gene in PSP Dr. William Johnson Robert Wood Johnson Medical School, New Brunswick, NJ
1998 Potential Role of Mitochondrial Defects in PSP Dr. Flint Beal Cornell University, Weill Medical College, New York, NY
1998 Trial of Donepezil HCL in PSP Patients Dr. Irene Litvan Henry M. Jackson Foundation, Bethesda, MD
1998 Establishment of a PSP Brain Bank Dr. Dennis Dickson Mayo Clinic, Jacksonville, FL
1997 Haplotype Relative Risk Analysis in PSP Dr. Lawrence Golbe Robert Wood Johnson Medical School, New Brunswick, NJ
1997 The History of PSP Dr. Adolfo Brusa Corso A. Saffi, Genoa, Italy
1997 Reaction Time and Acoustic Startle in Patients with PSP, Multi-System Atrophy, Barcelona and Parkinson’s Disease Dr. Josep Valls-Sole Hospital Clinic, Barcelona, Spain
1997 Linkage Analysis in Familial PSP (To Perform Linkage Analysis in a Large Spanish Family with PSP) Dr. Justo Garcia de Yebenes Universidad Autonoma de Madrid, Madrid, Spain
1997 Ferritin is Associated with the Aberant Tau Filaments Present in PSP Dr. Jesus Avila Centro De Biologica Molecular, Madrid, Spain
1997 Genetics and Environmental Studies of Bodig and Lytico in Villages of Southern Guam Dr. John Steele Tamuning, Guam 
1997 Presence and Amount of Glycation & Oxidation Markers in PSP Dr. Massimo Tabaton University of Genova, Italy